Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 2c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. MSFT
5. SPY
6. META
7. GMAB
8. GOOGL
9. AMD
10. BBIO

Go back to Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 2c, Revenues Beat

Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

August 6, 2020 7:31 AM EDT

Initiated Enrollment in Phase 1 Dose-Escalation Cohort Evaluating SY-5609 and Fulvestrant in Treatment-Resistant HR-Positive Breast Cancer Patients 

On Track to Report Clinical Data for SY-1425 and SY-5609 in Fourth Quarter of 2020

 Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and... More